Autoimmune Disease Drugs Market has a Solid Future

  • Autoimmune disease is a chronic health condition caused when the immune system starts attacking its own body's cells.
  • Increasing improvements in government regulations and growing drug approvals expected to boost market growth.
  • The market in North America is anticipated to observe greater growth opportunities on account of increasing research and development activities.

Autoimmune disease is a chronic health condition caused when the immune system starts attacking its own body’s cells. The Centers for Disease Prevention and Control reports around 22.7% or 54.4 million adults in America had doctor-diagnosed arthritis as per the National Health Interview Survey 2013-2015, with a higher prevalence in women (23.5%) than in men (18.1%).

Autoimmune disease can be either localized or systemic. The market for autoimmune disease drugs is anticipated to record a CAGR of around 5% over the forecast period, i.e., 2020-2028. The market is segmented by drug, by disease, by distribution channel and by region. Based on drugs, the

Autoimmune disease is a chronic health condition caused when the immune system starts attacking its own body’s cells.

market is segmented into NSAIDs, anti-inflammatory, interferons, antihyperglycemics and others, out of which, the anti-inflammatory segment is anticipated to hold the largest share in the autoimmune disease drugs market on the back of high number of applications of this drug. Anti-inflammatory drugs can be used to treat disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, gout, psoriasis, ankylosing spondylitis and others.

Regional Analysis

On the basis of geography, the autoimmune disease drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is anticipated to observe greater growth opportunities on account of increasing research and development activities focused on finding a cure for autoimmune disease. On the other hand, the market in Asia Pacific is predicted to grow at the highest rate as a result of improving healthcare infrastructure and development of better treatment facilities.

The rising number of drugs being approved for the treatment of various autoimmune disorders is a major growth driving factor for the autoimmune disease drugs market. Moreover, the increasing research and development in the area of autoimmune disease is predicted to lead to more drug approvals in the coming years. However, the high cost of treatment for autoimmune disease is estimated to hamper the market growth over the forecast period.

Download Sample of This Strategic Report

The rising number of drugs being approved for the treatment of various autoimmune disorders is a major growth driving factor for the autoimmune disease drugs market.

 

Competitive Landscape

This report also provides the existing competitive scenario of some of the key players of the global autoimmune disease drugs market which includes company profiling of Abbott Laboratories, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, AstraZeneca plc, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Biogen and Amgen. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments.

On the whole, the report depicts detailed overview of the global autoimmune disease drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market-centric strategies according to the ongoing and expected trends in the future.

Only $1/click

Submit Your Ad Here

Leave a Reply